@OncIDPharmd Finlandograms and MIC distribution histograms are back!
Thanks for your patience and the interest in the SENTRY program. https://t.co/1aUAVw5D9g
"The potent in vitro activity of sulopenem against this large collection of recent Enterobacterales and anaerobic clinical isolates from various infection types support its further clinical evaluation to treat IAIs and UTIs"
https://t.co/Dj0Tv8c9nr
@jmilabs#OpenAccess#JACNews
🤝 We are entering into a 6-year collaboration with @jmilabs to undertake to evaluate the performance and increasing potential of rapid and innovative microbiology diagnostics as important tools in the battle against #AMR.
Read more: https://t.co/x9SazCfBqL
@ElementTesting
Congratulations to our team at @jmilabs who are partnering with @biomerieux to fight #antimicrobial resistance. 🦠
Read more here: https://t.co/2FYBeANgkx
“Aztreonam/avibactam activity was not adversely affected by clinically relevant CPEs. Our results support aztreonam/avibactam development to treat infections caused by CRE, including MBL producers”
https://t.co/SBDWKOiT8G
@jmilabs@heliosader#JACAMRNews
Just discovered the @jmilabs SENTRY database’s public-facing page (late to the party, I know).
This is SO COOL for looking at resistance rates/patterns! Can also do granular queries for specific genes/phenotypes/bugs/etc.
https://t.co/JWOg4gitDo
.@AMAManual, do you have an official designation for which countries fall into Eastern vs. Western Europe? And, if so, how was this divided? By WHO regulations or something else?
Fellows in-training, residents and medical students are invited to present cases at #IDWeek2023. Selected cases will be featured in Fellows’ Day workshops, and travel grants up to $800 are available to cover expenses.
Submit your case by May 3: https://t.co/X3v1aWPrUZ
Incredibly informative report from the team at @jmilabs on longitudinal (2016-2020) resistance patterns in E. coli and K. pneumo.
Lots of pertinent info but a few things that stood out:
Link: https://t.co/NIPvMf5JuR